Penumbra, Inc. (NYSE:PEN) Shares Sold by Invesco Ltd.

Invesco Ltd. decreased its holdings in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 14.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 49,524 shares of the company's stock after selling 8,556 shares during the period. Invesco Ltd. owned 0.13% of Penumbra worth $11,761,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. UMB Bank n.a. increased its position in shares of Penumbra by 57.4% during the fourth quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $46,000 after acquiring an additional 70 shares in the last quarter. Hurley Capital LLC purchased a new stake in shares of Penumbra during the fourth quarter valued at $56,000. Huntington National Bank increased its holdings in Penumbra by 138.7% in the 4th quarter. Huntington National Bank now owns 265 shares of the company's stock worth $63,000 after buying an additional 154 shares in the last quarter. Mather Group LLC. lifted its position in Penumbra by 208.0% during the fourth quarter. Mather Group LLC. now owns 308 shares of the company's stock valued at $73,000 after purchasing an additional 208 shares during the period. Finally, Jones Financial Companies Lllp grew its position in Penumbra by 25.0% in the 4th quarter. Jones Financial Companies Lllp now owns 375 shares of the company's stock worth $89,000 after purchasing an additional 75 shares during the period. 88.88% of the stock is currently owned by hedge funds and other institutional investors.

Penumbra Stock Up 0.3 %

Shares of NYSE:PEN traded up $0.96 during trading on Wednesday, reaching $278.18. The stock had a trading volume of 834,531 shares, compared to its average volume of 417,714. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $10.76 billion, a P/E ratio of 818.18, a PEG ratio of 2.83 and a beta of 0.56. The firm's 50-day simple moving average is $275.79 and its 200 day simple moving average is $252.92. Penumbra, Inc. has a one year low of $148.00 and a one year high of $310.00.

Penumbra (NYSE:PEN - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.66 by $0.17. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. As a group, research analysts expect that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on PEN shares. StockNews.com cut Penumbra from a "buy" rating to a "hold" rating in a research report on Friday, February 28th. Needham & Company LLC reaffirmed a "hold" rating on shares of Penumbra in a report on Wednesday, February 19th. Royal Bank of Canada reissued an "outperform" rating and set a $315.00 price objective on shares of Penumbra in a research report on Tuesday, April 15th. Wells Fargo & Company raised their target price on Penumbra from $275.00 to $305.00 and gave the stock an "overweight" rating in a report on Wednesday, February 19th. Finally, Canaccord Genuity Group boosted their price target on Penumbra from $323.00 to $340.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $293.93.

Insider Transactions at Penumbra

In other Penumbra news, Director Arani Bose sold 12,000 shares of the firm's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $283.77, for a total value of $3,405,240.00. Following the completion of the transaction, the director now owns 314,819 shares of the company's stock, valued at approximately $89,336,187.63. This trade represents a 3.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Adam Elsesser sold 61,600 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $283.59, for a total transaction of $17,469,144.00. Following the sale, the chief executive officer now directly owns 16,376 shares in the company, valued at $4,644,069.84. This trade represents a 79.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 127,846 shares of company stock worth $35,779,187. Insiders own 5.00% of the company's stock.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.